Patents by Inventor Jay P. Powers

Jay P. Powers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9795599
    Abstract: Compounds of formula (I) are provided which are useful in the treatment of diseases or conditions modulated at least in part by CCR6:
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: October 24, 2017
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Daniel Dairaghi, Dean R. Dragoli, Jaroslaw Kalisiak, Christopher W. Lange, Manmohan Reddy Leleti, Yandong Li, Rebecca M. Lui, Venkat Reddy Mali, Viengkham Malathong, Jay P. Powers, Hiroko Tanaka, Joanne Tan, Matthew J. Walters, Ju Yang, Penglie Zhang
  • Patent number: 9783544
    Abstract: Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.
    Type: Grant
    Filed: August 26, 2015
    Date of Patent: October 10, 2017
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Junfa Fan, Antoni Krasinski, Christopher W. Lange, Rebecca M. Lui, Jeffrey P. McMahon, Jay P. Powers, Yibin Zeng, Penglie Zhang
  • Patent number: 9783540
    Abstract: Compounds are provided that are modulators of the CCR2 receptor. The compounds have the general formula (I): and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activtation of CCR2 receptors.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: October 10, 2017
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Junfa Fan, Jaroslaw Kalisiak, Rebecca M. Lui, Venkat Reddy Mali, Jeffrey P. McMahon, Jay P. Powers, Hiroko Tanaka, Yibin Zeng, Penglie Zhang
  • Patent number: 9750722
    Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are diazole lactam derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: September 5, 2017
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Xi Chen, Dean R. Dragoli, Pingchen Fan, Juan C. Jaen, Yandong Li, Jay P. Powers, Viengkham Malathong, Sreenivas Punna, Hiroko Tanaka, Penglie Zhang
  • Publication number: 20170204087
    Abstract: Oxindole compounds useful for the treatment of CCR(9) mediated conditions or diseases are provided.
    Type: Application
    Filed: January 18, 2017
    Publication date: July 20, 2017
    Inventors: Xi CHEN, Dean R. DRAGOLI, Pingchen FAN, Manmohan Reddy LELETI, Rebecca M. LUI, Viengkham MALATHONG, Jay P. POWERS, Rajinder SINGH, Hiroko TANAKA, Ju YANG, Chao YU, Penglie ZHANG
  • Publication number: 20160340356
    Abstract: Compounds are provided that are modulators of the CCR2 receptor. The compounds have the general formula (I): and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activtation of CCR2 receptors.
    Type: Application
    Filed: May 19, 2016
    Publication date: November 24, 2016
    Inventors: Junfa Fan, Jaroslaw Kalisiak, Rebecca M. Lui, Venkat Reddy Mali, Jeffrey P. McMahon, Jay P. Powers, Hiroko Tanaka, Yibin Zeng, Penglie Zhang
  • Publication number: 20160303084
    Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are diazole lactam derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists.
    Type: Application
    Filed: March 18, 2016
    Publication date: October 20, 2016
    Inventors: Xi Chen, Pingchen Fan, Yandong Li, Jay P. Powers, Viengkham Malathong, Sreenivas Punna, Hiroko Tanaka, Penglie Zhang
  • Publication number: 20160296508
    Abstract: Compounds of formula (I) are provided which are useful in the treatment of diseases or conditions modulated at least in part by CCR6:
    Type: Application
    Filed: March 18, 2016
    Publication date: October 13, 2016
    Inventors: Daniel Dairaghi, Dean R. Dragoli, Jarek Kalisiak, Christopher W. Lange, Manmohan Reddy Leleti, Yandong Li, Rebecca M. Lui, Venkat Reddy Mali, Viengkham Malathong, Jay P. Powers, Hiroko Tanaka, Joanne Tan, Matthew J. Walters, Ju Yang, Penglie Zhang
  • Publication number: 20160193185
    Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are diazole lactam derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists.
    Type: Application
    Filed: October 8, 2015
    Publication date: July 7, 2016
    Inventors: Xi CHEN, Dean R. DRAGOLI, Pingchen FAN, Juan C. JAEN, Yandong LI, Jay P. POWERS, Viengkham MALATHONG, Sreenivas PUNNA, Hiroko TANAKA, Penglie ZHANG
  • Publication number: 20160193191
    Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
    Type: Application
    Filed: October 8, 2015
    Publication date: July 7, 2016
    Inventors: Xi CHEN, Dean R. DRAGOLI, Pingchen FAN, Yandong LI, Jay P. POWERS, Sreenivas PUNNA, Hiroko TANAKA, Penglie ZHANG
  • Publication number: 20160145259
    Abstract: Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.
    Type: Application
    Filed: August 26, 2015
    Publication date: May 26, 2016
    Inventors: Junfa FAN, Antoni Krasinski, Christopher W. Lange, Rebecca M. Lui, Jeffrey P. McMahon, Jay P. Powers, Yibin Zeng, Penglie Zhang
  • Patent number: 9340509
    Abstract: Compounds of formula (I) are provided which are useful in the treatment of diseases or conditions modulated at least in part by CCR6:
    Type: Grant
    Filed: December 2, 2014
    Date of Patent: May 17, 2016
    Assignee: ChemoCentryx, Inc.
    Inventors: Daniel Dairaghi, Dean R. Dragoli, Jarek Kalisiak, Christopher W. Lange, Manmohan Reddy Leleti, Yandong Li, Rebecca M. Lui, Venkat Reddy Mali, Viengkham Malathong, Jay P. Powers, Hiroko Tanaka, Joanne Tan, Matthew J. Walters, Ju Yang, Penglie Zhang
  • Patent number: 9328116
    Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are diazole lactam derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists.
    Type: Grant
    Filed: December 6, 2013
    Date of Patent: May 3, 2016
    Assignee: ChemoCentryx, Inc.
    Inventors: Xi Chen, Pingchen Fan, Yandong Li, Jay P. Powers, Viengkham Malathong, Sreenivas Punna, Hiroko Tanaka, Penglie Zhang, Dean Dragoli
  • Patent number: 9181241
    Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
    Type: Grant
    Filed: August 27, 2013
    Date of Patent: November 10, 2015
    Assignee: ChemoCentryx, Inc.
    Inventors: Xi Chen, Dean R. Dragoli, Pingchen Fan, Yandong Li, Jay P. Powers, Sreenivas Punna, Hiroko Tanaka, Penglie Zhang
  • Patent number: 9169248
    Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are diazole lactam derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: October 27, 2015
    Assignee: ChemoCentryx, Inc.
    Inventors: Xi Chen, Dean R. Dragoli, Pingchen Fan, Juan C. Jaen, Yandong Li, Jay P. Powers, Viengkham Malathong, Sreenivas Punna, Hiroko Tanaka, Penglie Zhang
  • Patent number: 9169261
    Abstract: Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.
    Type: Grant
    Filed: November 27, 2013
    Date of Patent: October 27, 2015
    Assignee: ChemoCentryx, Inc.
    Inventors: Junfa Fan, Antoni Krasinski, Christopher W. Lange, Rebecca M. Lui, Jeffrey P. McMahon, Jay P. Powers, Yibin Zeng, Penglie Zhang
  • Publication number: 20150175547
    Abstract: Compounds of formula (I) are provided which are useful in the treatment of diseases or conditions modulated at least in part by CCR6:
    Type: Application
    Filed: December 2, 2014
    Publication date: June 25, 2015
    Inventors: Daniel Dairaghi, Dean R. Dragoli, Jarek Kalisiak, Christopher W. Lange, Manmohan Reddy Leleti, Yandong Li, Rebecca M. Lui, Venkat Reddy Mali, Viengkham Malathong, Jay P. Powers, Hiroko Tanaka, Joanne Tan, Matthew J. Walters, Ju Yang, Penglie Zhang
  • Publication number: 20150073017
    Abstract: Compounds are provided that act as potent antagonists of the CCR(9) receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR(9). The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR(9)-mediated diseases, and as controls in assays for the identification of CCR(9) antagonists.
    Type: Application
    Filed: November 14, 2014
    Publication date: March 12, 2015
    Inventors: Xi CHEN, Junfa FAN, Pingchen FAN, Antoni KRASINSKI, Lianfa LI, Rebecca M. LUI, Jeffrey P. McMAHON, Jay P. POWERS, Yibin ZENG, Penglie ZHANG
  • Patent number: 8916601
    Abstract: Compounds are provided that act as potent antagonists of the CCR(9) receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR(9). The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR(9)-mediated diseases, and as controls in assays for the identification of CCR(9) antagonists.
    Type: Grant
    Filed: February 28, 2013
    Date of Patent: December 23, 2014
    Assignee: ChemoCentryx, Inc.
    Inventors: Xi Chen, Junfa Fan, Pingchen Fan, Antoni Krasinski, Lianfa Li, Rebecca M. Lui, Jeffrey P. McMahon, Jay P. Powers, Yibin Zeng, Penglie Zhang
  • Patent number: 8906938
    Abstract: Compounds are provided that are modulators of the C5a receptor. The compounds are substituted piperidines and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activation of C5a receptors.
    Type: Grant
    Filed: May 14, 2013
    Date of Patent: December 9, 2014
    Assignee: ChemoCentryx, Inc.
    Inventors: Pingchen Fan, Kevin Lloyd Greenman, Manmohan Reddy Leleti, Yandong Li, Jay P. Powers, Hiroko Tanaka, Ju Yang, Yibin Zeng